MK-677, also known as Ibutamoren Mesylate or MK-0677, is an orally active, non-peptide growth-hormone secretagogue identified by CAS Number 159752-10-0. It interacts with the growth-hormone secretagogue receptor, a receptor also involved in ghrelin signalling, and has been investigated for its effects on growth-hormone and insulin-like growth factor 1 pathways.
Nova Techsciences associates this compound with its NOVAMOREN tablet range. However, information published on an MK-677 compound page should clearly distinguish chemical identification and investigational research from an authorised therapeutic indication.
MK-677 Quick Facts
- Compound name: Ibutamoren Mesylate
- Alternative names: MK-677 and MK-0677
- CAS Number: 159752-10-0
- Compound type: Non-peptide growth-hormone secretagogue
- Pharmaceutical form: Commonly investigated as an oral compound
- Associated Nova Techsciences range: NOVAMOREN
The compound name, CAS number, strength and formulation should remain consistent across product labels, technical files, structured data, Certificates of Analysis and batch records.
Scientific and Regulatory Context
The European Commission granted Ibutamoren Mesylate an orphan designation in 2017 for investigation in growth-hormone deficiency. The European Medicines Agency states clearly that orphan designation is not a marketing authorisation. Quality, safety and efficacy must still be demonstrated before a medicine can receive authorisation.
MK-677 has also been evaluated in clinical studies involving older adults and other patient populations. These studies should not be interpreted as approval for general hormone enhancement, muscle development or wellness use.
For audiences in the Netherlands, United Kingdom and other European markets, Nova Techsciences should clearly disclose the compound’s current authorisation status, intended-use limitations, responsible organisation and adverse-event reporting process.
Quality Control and Traceability
A reliable compound page should be supported by appropriate analytical documentation. Relevant controls may include raw-material identity testing, active-compound assay, impurity assessment, reference-standard comparison, tablet content uniformity, dissolution testing, stability evaluation and packaging-integrity checks.
Each manufactured batch should carry a unique identification number linked to its production history and laboratory-release results. Claims concerning purity, pharmaceutical quality or manufacturing compliance should only appear when supported by current documentation.
Safety Information
Clinical research has reported changes in glucose regulation during MK-677 administration. In one randomised study, fasting blood glucose increased and insulin sensitivity decreased. The FDA also warns that Ibutamoren is not an approved active ingredient in the United States and may cause increased appetite, fluid retention, fatigue, muscle discomfort and altered glucose metabolism.
MK-677 should not be presented for unsupervised bodybuilding, recovery enhancement, self-medication or use by minors. It is also listed by WADA among prohibited growth-hormone-releasing factors.
Related Nova Techsciences Compounds
Methandienone
Methandienone is an orally active anabolic-androgenic steroid identified by CAS Number 72-63-9. It is chemically and pharmacologically different from Ibutamoren and requires separate information covering liver, cardiovascular, hormonal and reproductive risks, regulatory status and batch traceability.
Clenbuterol Hydrochloride
Clenbuterol Hydrochloride is a beta-adrenergic agonist identified by CAS Number 21898-19-1. It is not a growth-hormone secretagogue and has separate cardiovascular and nervous-system safety considerations. Its authorised status varies between markets and must be communicated accurately.
Stanozolol USP
Stanozolol USP is an anabolic-androgenic steroid identified by CAS Number 10418-03-8. It has a distinct chemical identity and safety profile from MK-677. Its page should independently address regulatory status, liver-related risks, cardiovascular precautions and quality documentation.
Stanozolol STANOVA-50
STANOVA-50 represents a higher-strength Stanozolol presentation rather than a separate active compound. It retains CAS Number 10418-03-8, while the formulation strength, pack details, batch information and warnings should be clearly distinguished from lower-strength presentations.
Clomiphene Citrate
Clomiphene Citrate is a selective oestrogen receptor modulator identified by CAS Number 50-41-9. It is associated with medically supervised reproductive treatment and requires separate information covering visual adverse effects, ovarian response, contraindications and prescription requirements.
MK-677 should ultimately be presented through accurate chemical identification, transparent scientific evidence, documented quality controls and clearly stated regulatory limitations.